Log in to save to my catalogue
Log in to save to my catalogue

EGFR activation limits the response of liver cancer to lenvatinib

| Ask | Become a Library member

EGFR activation limits the response of liver cancer to lenvatinib

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2556441351

EGFR activation limits the response of liver cancer to lenvatinib

About this item

Publication information

Publisher

London: Nature Publishing Group UK

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Hepatocellular carcinoma (HCC)—the most common form of liver cancer—is an aggressive malignancy with few effective treatment options
1
. Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only limited clinical benefit
2
. Here, us...

Alternative Titles

Full title

EGFR activation limits the response of liver cancer to lenvatinib

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2556441351

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2556441351

Other Identifiers

ISSN

0028-0836

E-ISSN

1476-4687

DOI

10.1038/s41586-021-03741-7

How to access this item

Log in as a Library member

View record in Gale

About resource

View in old catalogue

Connecting people and collections